Background: Physalis angulata L. fruit (ciplukan) is rich in immunostimulatory compounds but exhibits poor water solubility. To enhance its efficacy, particle size reduction into microparticle extract (ekstrak mikropartikel buah ciplukan/EMC) combined with propolis in a lozenge formulation was developed. Objective: This study aimed to characterize EMC, evaluate its safety in vitro and in vivo in Wistar rats, and formulate and assess the immunostimulatory activity of the combination lozenges. Methods: EMC was characterized using scanning electron microscopy (SEM), particle size analyzer (PSA), and phytochemical screening. In vitro safety was evaluated using RAW 264.7 cell line. In vivo safety evaluation included organ index, hematological parameters, splenic histology (white pulp diameter), and hepatic mannose receptor (CD206) expression. Lozenges containing a combination of EMC, propolis, vitamin C, vitamin D, and zinc (Zn) were formulated and evaluated for its immunostimulatory activity in vivo. Results: EMC exhibited a spherical morphology and was rich in phenolic compounds, flavonoids, and alkaloids. RAW 264.7 cell viability remained >100% up to a concentration of 500 ppm, indicating the absence of cytotoxic effects. In vivo, EMC at a dose of 37.8 mg/kg body weight/BW (equivalent to human dosage of 300 mg EMC/70 kg BW) significantly increased white blood cell profiles (leukocytes, lymphocytes, monocytes, and granulocytes), splenic white pulp diameter (reaching 531.81 μm), and hepatic CD206 expression (reaching 25.721%) compared to the negative control and gallic acid comparator groups (p<0.05). The combined lozenge formulation containing both extracts also significantly enhanced all evaluated immunological parameters compared to the negative control (p<0.05). Conclusion: The combined EMC and propolis extract lozenge formulation shows potential for further development as an alternative formulation to support the body’s defense system.
Copyrights © 2026